redorbit.com
May 14, 2008
NATICK, Mass., May 13 /PRNewswire-FirstCall/ -- Boston Scientific Corporation today announced U.S. Food and Drug Administration (FDA) approval of its COGNIS(TM) cardiac resynchronization therapy defibrillator (CRT-D) and TELIGEN(TM) implantable cardioverter defibrillator (ICD).
[read full story]